Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring Oct 14 | 2019Abbott Libre 2 US Approval Conspicuously Late?Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring Oct 08 | 2019Intarcia Re-files ITCA-650; New Dexcom G6 Professional CGM; One Drop/Walmart PartnershipPurchase Blast
$599
Posted in: Insulin Delivery Oct 04 | 2019New Medtronic Extended Wear Infusion Set TrialPurchase Blast
$599
Posted in: Basal Insulin Oct 02 | 2019Mylan Faces Setback in Sanofi Bs-Glargine LawsuitPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other Oct 01 | 2019Sanofi to Unveil New Strategy in December; Novo Obesity Partnership; Lifescan to Expand BGM AccessPurchase Blast
$599
Posted in: Glucose Monitoring Sep 30 | 2019Senseonics Completes Enrollment for 180-Day CGM TrialPurchase Blast
$599
Posted in: SGLT2i Sep 30 | 2019CREDENCE Label Update for Invokana is a Big Win for JanssenPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, SGLT2i Sep 24 | 2019Sanofi DCV R&D Head Set to Move OnPurchase Blast
$599
Posted in: Glucagon Sep 24 | 2019Zealand Dasiglucagon Pediatric Study Meets Primary and Secondary EndpointsPurchase Blast
$599
Posted in: Insulin Delivery Sep 23 | 2019Insulet Omnipod DASH Pump Receives Interoperability DesignationPurchase Blast
$599
Posted in: DPP-IVi, SGLT2i Sep 23 | 2019AZ's Triple FDC (Dapa/Saxa/Met) Receives Positive CHMP OpinionPurchase Blast
$599
Posted in: GLP-1RA Sep 23 | 2019Novo Hosts Post-approval Rybelsus Investor Call; Semaglutide HFpEF Study?Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Sep 19 | 2019New MannKind and Dance Inhaled Insulin Data; EASD 2019 Day 4Purchase Blast
$599
Posted in: Basal Insulin Sep 19 | 2019Thoughts on CONCLUDE (H2H Tresiba vs. Toujeo T2DM Basal-only Trial)Purchase Blast
$599
Posted in: SGLT2i Sep 19 | 2019Lexicon +188% Post DAPA-HF and Sanofi Partnership DissolutionPurchase Blast$599
Posted in: Dual/triple agonist, Other Sep 18 | 2019Poxel Ph3 Imeglimin and vTv Ph2 TTP399 CGM Data; EASD 2019 Day 3Purchase Blast